Skip to main content
Published Online:https://doi.org/10.1259/bjr.20210576

Abstract

FDG-PET scanning has a central role in lymphoma staging and response assessment. There is a growing body of evidence that PET response assessment during and after initial systemic therapy can provide useful prognostic information, and PET response has an evolving role in guiding patient care. This review provides a perspective on the role of PET response assessment for individualised management of patients with the most common aggressive lymphomas, Hodgkin lymphoma and diffuse large B-cell lymphoma.

REFERENCES

  • 1. Juweid ME, , Stroobants S, , Hoekstra OS, , Mottaghy FM, , Dietlein M, , Guermazi A, , et al.. Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging Subcommittee of international harmonization project in lymphoma. J Clin Oncol 2007; 25: 571–8. doi: https://doi.org/10.1200/JCO.2006.08.2305 http://www.ncbi.nlm.nih.gov/pubmed/17242397 Crossref Medline ISIGoogle Scholar

  • 2. Barrington SF, , Mikhaeel NG, , Kostakoglu L, , Meignan M, , Hutchings M, , Müeller SP, , et al.. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on malignant lymphomas imaging Working group. J Clin Oncol 2014; 32: 3048–58. doi: https://doi.org/10.1200/JCO.2013.53.5229 http://www.ncbi.nlm.nih.gov/pubmed/25113771 Crossref Medline ISIGoogle Scholar

  • 3. Barrington SF, , Qian W, , Somer EJ, , Franceschetto A, , Bagni B, , Brun E, , et al.. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 2010; 37: 1824–33. doi: https://doi.org/10.1007/s00259-010-1490-5 http://www.ncbi.nlm.nih.gov/pubmed/20505930 Crossref Medline ISIGoogle Scholar

  • 4. Cheson BD, , Fisher RI, , Barrington SF, , Cavalli F, , Schwartz LH, , Zucca E, , et al.. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014; 32: 3059–68. doi: https://doi.org/10.1200/JCO.2013.54.8800 http://www.ncbi.nlm.nih.gov/pubmed/25113753 Crossref Medline ISIGoogle Scholar

  • 5. Radford J, , Illidge T, , Counsell N, , Hancock B, , Pettengell R, , Johnson P, , et al.. Results of a trial of PET-directed therapy for early-stage hodgkin’s lymphoma. New England Journal of Medicine 2015; 372: 1598–607. doi: https://doi.org/10.1056/NEJMoa1408648 Crossref Medline ISIGoogle Scholar

  • 6. André MPE, , Girinsky T, , Federico M, , Reman O, , Fortpied C, , Gotti M, , et al.. Early positron emission tomography Response-Adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 2017; 35: 1786–94. doi: https://doi.org/10.1200/JCO.2016.68.6394 http://www.ncbi.nlm.nih.gov/pubmed/28291393 Crossref MedlineGoogle Scholar

  • 7. Fuchs M, , Goergen H, , Kobe C, , Kuhnert G, , Lohri A, , Greil R, , et al.. Positron emission Tomography-Guided treatment in early-stage favorable Hodgkin lymphoma: final results of the International, randomized phase III HD16 trial by the German Hodgkin Study Group. J Clin Oncol 2019; 37: 2835–45. doi: https://doi.org/10.1200/JCO.19.00964 http://www.ncbi.nlm.nih.gov/pubmed/31498753 Crossref MedlineGoogle Scholar

  • 8. Straus DJ, , Jung S-H, , Pitcher B, , Kostakoglu L, , Grecula JC, , Hsi ED, , et al.. CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. Blood 2018; 132: 1013–21. doi: https://doi.org/10.1182/blood-2018-01-827246 http://www.ncbi.nlm.nih.gov/pubmed/30049811 Crossref Medline ISIGoogle Scholar

  • 9. Borchmann P, , Plütschow A, , Kobe C, , Greil R, , Meissner J, , Topp MS, , et al.. PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2021; 22: 223–34. doi: https://doi.org/10.1016/S1470-2045(20)30601-X http://www.ncbi.nlm.nih.gov/pubmed/33539742 Crossref Medline ISIGoogle Scholar

  • 10. Raemaekers JMM, , André MPE, , Federico M, , Girinsky T, , Oumedaly R, , Brusamolino E, , et al.. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 2014; 32: 1188–94. doi: https://doi.org/10.1200/JCO.2013.51.9298 http://www.ncbi.nlm.nih.gov/pubmed/24637998 Crossref Medline ISIGoogle Scholar

  • 11. Schaapveld M, , Aleman BMP, , van Eggermond AM, , Janus CPM, , Krol ADG, , van der Maazen RWM, , et al.. Second cancer risk up to 40 years after treatment for hodgkin’s lymphoma. New England Journal of Medicine 2015; 373: 2499–511. doi: https://doi.org/10.1056/NEJMoa1505949 Crossref Medline ISIGoogle Scholar

  • 12. Henson KE, , Reulen RC, , Winter DL, , Bright CJ, , Fidler MM, , Frobisher C, , et al.. Cardiac mortality among 200 000 five-year survivors of cancer diagnosed at 15 to 39 years of age: the teenage and young adult cancer survivor study. Circulation 2016; 134: 1519–31. doi: https://doi.org/10.1161/CIRCULATIONAHA.116.022514 http://www.ncbi.nlm.nih.gov/pubmed/27821538 Crossref Medline ISIGoogle Scholar

  • 13. Barrington SF, , Phillips EH, , Counsell N, , Hancock B, , Pettengell R, , Johnson P, , et al.. Positron emission tomography score has greater prognostic significance than pretreatment risk stratification in early-stage Hodgkin lymphoma in the UK rapid study. J Clin Oncol 2019; 37: 1732–41. doi: https://doi.org/10.1200/JCO.18.01799 http://www.ncbi.nlm.nih.gov/pubmed/31112475 Crossref Medline ISIGoogle Scholar

  • 14. Eich HT, , Diehl V, , Görgen H, , Pabst T, , Markova J, , Debus J, , et al.. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin study group HD11 trial. J Clin Oncol 2010; 28: 4199–206. doi: https://doi.org/10.1200/JCO.2010.29.8018 http://www.ncbi.nlm.nih.gov/pubmed/20713848 Crossref Medline ISIGoogle Scholar

  • 15. Johnson P, , Federico M, , Kirkwood A, , Fosså A, , Berkahn L, , Carella A, , et al.. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma. N Engl J Med 2016; 374: 2419–29. doi: https://doi.org/10.1056/NEJMoa1510093 http://www.ncbi.nlm.nih.gov/pubmed/27332902 Crossref Medline ISIGoogle Scholar

  • 16. Kumar A, , Burger IA, , Zhang Z, , Drill EN, , Migliacci JC, , Ng A, , et al.. Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planes. Haematologica 2016; 101: 1237–43. doi: https://doi.org/10.3324/haematol.2016.141846 http://www.ncbi.nlm.nih.gov/pubmed/27390360 Crossref Medline ISIGoogle Scholar

  • 17. Illidge TM, , Phillips EH, , Counsell N, , Pettengell R, , Johnson PWM, , Culligan DJ, , et al.. Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I/IIa Hodgkin lymphoma. Blood Adv 2020; 4: 203–6. doi: https://doi.org/10.1182/bloodadvances.2019001023 http://www.ncbi.nlm.nih.gov/pubmed/31935289 Crossref Medline ISIGoogle Scholar

  • 18. Klimm B, , Goergen H, , Fuchs M, , von Tresckow B, , Böll B, , Meissner J, , et al.. Impact of risk factors on outcomes in early-stage Hodgkin's lymphoma: an analysis of international staging definitions. Ann Oncol 2013; 24: 3070–6. doi: https://doi.org/10.1093/annonc/mdt413 http://www.ncbi.nlm.nih.gov/pubmed/24148816 Crossref Medline ISIGoogle Scholar

  • 19. Zinzani PL, , Broccoli A, , Gioia DM, , Castagnoli A, , Ciccone G, , Evangelista A, , et al.. Interim positron emission tomography Response-Adapted therapy in advanced-stage Hodgkin lymphoma: final results of the phase II part of the HD0801 study. J Clin Oncol 2016; 34: 1376–85. doi: https://doi.org/10.1200/JCO.2015.63.0699 http://www.ncbi.nlm.nih.gov/pubmed/26884559 Crossref Medline ISIGoogle Scholar

  • 20. Gallamini A, , Tarella C, , Viviani S, , Rossi A, , Patti C, , Mulé A, , et al.. Early chemotherapy intensification with Escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography/computed tomography scan after two ABVD cycles: long-term results of the GITIL/FIL HD 0607 trial. J Clin Oncol 2018; 36: 454–62. doi: https://doi.org/10.1200/JCO.2017.75.2543 http://www.ncbi.nlm.nih.gov/pubmed/29360414 Medline ISIGoogle Scholar

  • 21. Borchmann P, , Goergen H, , Kobe C, , Lohri A, , Greil R, , Eichenauer DA, , et al.. PET-guided treatment in patients with advanced-stage Hodgkin’s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. The Lancet 2017; 390: 2790–802. doi: https://doi.org/10.1016/S0140-6736(17)32134-7 Crossref Medline ISIGoogle Scholar

  • 22. Casasnovas R-O, , Bouabdallah R, , Brice P, , Lazarovici J, , Ghesquieres H, , Stamatoullas A, , et al.. PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. Lancet Oncol 2019; 20: 202–15. doi: https://doi.org/10.1016/S1470-2045(18)30784-8 http://www.ncbi.nlm.nih.gov/pubmed/30658935 Crossref Medline ISIGoogle Scholar

  • 23. Straus DJ, , Długosz-Danecka M, , Alekseev S, , Illés Árpád, , Picardi M, , Lech-Maranda E, , et al.. Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Blood 2020; 135: 735–42. doi: https://doi.org/10.1182/blood.2019003127 http://www.ncbi.nlm.nih.gov/pubmed/31945149 Crossref Medline ISIGoogle Scholar

  • 24. Stephens DM, , Li H, , Schöder H, , Straus DJ, , Moskowitz CH, , LeBlanc M, , et al.. Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. Blood 2019; 134: 1238–46. doi: https://doi.org/10.1182/blood.2019000719 http://www.ncbi.nlm.nih.gov/pubmed/31331918 Crossref Medline ISIGoogle Scholar

  • 25. Gallamini A, , Hutchings M, , Rigacci L, , Specht L, , Merli F, , Hansen M, , et al.. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007; 25: 3746–52. doi: https://doi.org/10.1200/JCO.2007.11.6525 http://www.ncbi.nlm.nih.gov/pubmed/17646666 Crossref Medline ISIGoogle Scholar

  • 26. Hutchings M, , Loft A, , Hansen M, , Pedersen LM, , Buhl T, , Jurlander J, , et al.. Fdg-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006; 107: 52–9. doi: https://doi.org/10.1182/blood-2005-06-2252 http://www.ncbi.nlm.nih.gov/pubmed/16150944 Crossref Medline ISIGoogle Scholar

  • 27. Hutchings M, , Mikhaeel NG, , Fields PA, , Nunan T, , Timothy AR. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 2005; 16: 1160–8. doi: https://doi.org/10.1093/annonc/mdi200 http://www.ncbi.nlm.nih.gov/pubmed/15939713 Crossref Medline ISIGoogle Scholar

  • 28. André MPE, , Carde P, , Viviani S, , Bellei M, , Fortpied C, , Hutchings M, , et al.. Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: a pooled analysis of four randomized trials. Cancer Med 2020; 9: 6565–75. doi: https://doi.org/10.1002/cam4.3298 http://www.ncbi.nlm.nih.gov/pubmed/32710498 Crossref Medline ISIGoogle Scholar

  • 29. Casasnovas O, , Racape J, , Dechene J, , Bouabdallah R, , Brice P, , Lazarovici J, , et al.. PET-Guided strategy improves the safety of Beacopp-Based treatment in advanced Hodgkin lymphoma: prolonged follow-up of the lysA Ahl 2011 phase 3 study. Blood 2020; 136(Supplement 1): 23–4. doi: https://doi.org/10.1182/blood-2020-136056 CrossrefGoogle Scholar

  • 30. Vijenthira A, , Chan K, , Cheung MC, , Prica A. Cost-Effectiveness of first-line treatment options for patients with advanced-stage Hodgkin lymphoma: a modelling study. Lancet Haematol 2020; 7: e146–56. doi: https://doi.org/10.1016/S2352-3026(19)30218-2 http://www.ncbi.nlm.nih.gov/pubmed/31948928 Crossref Medline ISIGoogle Scholar

  • 31. Ricardi U, , Levis M, , Evangelista A, , Gioia DM, , Rigacci L, , Botto B, , et al.. OC-0502 role of consolidation RT to bulky lesions of advanced Hodgkin lymphoma: results of FIL HD0801 trial. Radiotherapy and Oncology 2019; 133: S258–9. doi: https://doi.org/10.1016/S0167-8140(19)30922-3 Crossref ISIGoogle Scholar

  • 32. Engert A, , Haverkamp H, , Kobe C, , Markova J, , Renner C, , Ho A, , et al.. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. The Lancet 2012; 379: 1791–9. doi: https://doi.org/10.1016/S0140-6736(11)61940-5 Crossref Medline ISIGoogle Scholar

  • 33. Landman-Parker J, , Wallace H, , Hasenclever D, , Balwierz W, , Karlen J, , Fossa A. P064: first international INTER-GROUP study for classical Hodgkin lymphoma in children and adolescents: EuroNet-PHL-C1. Report of the latest interim analysis. Haematologica 2016; 101: 35. Google Scholar

  • 34. Hoppe RT, , Advani RH, , Ai WZ, , Ambinder RF, , Armand P, , Bello CM, , et al.. Hodgkin lymphoma, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2020; 18: 755–81. doi: https://doi.org/10.6004/jnccn.2020.0026 http://www.ncbi.nlm.nih.gov/pubmed/32502987 Crossref Medline ISIGoogle Scholar

  • 35. Borchmann S, , Müller H, , Haverkamp H, , Baues C, , Marková J, , Hüttmann A, , et al.. Symptomatic osteonecrosis as a treatment complication in Hodgkin lymphoma: an analysis of the German Hodgkin study group (GHSG). Leukemia 2019; 33: 439–46. doi: https://doi.org/10.1038/s41375-018-0240-8 http://www.ncbi.nlm.nih.gov/pubmed/30131583 Crossref Medline ISIGoogle Scholar

  • 36. Miller TP, , Unger JM, , Spier C, , Stea B, , Cantu E, , LeBlanc M, , et al.. Effect of adding rituximab to three cycles of CHOP plus Invoved-Field radiotherapy for limited-stage aggressive diffuse B-cell lymphoma (SWOG-0014. Blood 2004; 104(suppl): 158–9. doi: https://doi.org/10.1182/blood.V104.11.158.158 CrossrefGoogle Scholar

  • 37. Miller TP, , Dahlberg S, , Cassady JR, , Adelstein DJ, , Spier CM, , Grogan TM, , et al.. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998; 339: 21–6. doi: https://doi.org/10.1056/NEJM199807023390104 http://www.ncbi.nlm.nih.gov/pubmed/9647875 Crossref Medline ISIGoogle Scholar

  • 38. Lamy T, , Damaj G, , Soubeyran P, , Gyan E, , Cartron G, , Bouabdallah K, , et al.. R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. Blood 2018; 131: 174–81. doi: https://doi.org/10.1182/blood-2017-07-793984 http://www.ncbi.nlm.nih.gov/pubmed/29061568 Crossref Medline ISIGoogle Scholar

  • 39. Horning SJ, , Weller E, , Kim K, , Earle JD, , O'Connell MJ, , Habermann TM, , et al.. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: eastern cooperative Oncology group study 1484. J Clin Oncol 2004; 22: 3032–8. doi: https://doi.org/10.1200/JCO.2004.06.088 http://www.ncbi.nlm.nih.gov/pubmed/15210738 Crossref Medline ISIGoogle Scholar

  • 40. Pfreundschuh M, , Ho AD, , Cavallin-Stahl E, , Wolf M, , Pettengell R, , Vasova I, , et al.. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera international trial Group (mint) study. Lancet Oncol 2008; 9: 435–44. doi: https://doi.org/10.1016/S1470-2045(08)70078-0 http://www.ncbi.nlm.nih.gov/pubmed/18400558 Medline ISIGoogle Scholar

  • 41. Poeschel V, , Held G, , Ziepert M, , Witzens-Harig M, , Holte H, , Thurner L, , et al.. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (flyer): a randomised, phase 3, non-inferiority trial. Lancet 2019; 394: 2271–81. doi: https://doi.org/10.1016/S0140-6736(19)33008-9 http://www.ncbi.nlm.nih.gov/pubmed/31868632 Crossref Medline ISIGoogle Scholar

  • 42. Persky DO, , Li H, , Stephens DM, , Park SI, , Bartlett NL, , Swinnen LJ, , et al.. Positron emission Tomography-Directed therapy for patients with limited-stage diffuse large B-cell lymphoma: results of intergroup national clinical trials network study S1001. J Clin Oncol 2020; 38: 3003–11. doi: https://doi.org/10.1200/JCO.20.00999 http://www.ncbi.nlm.nih.gov/pubmed/32658627 Crossref Medline ISIGoogle Scholar

  • 43. Pfreundschuh M, , Murawski N, , Ziepert M, , Altmann B, , Dreyling MH, , Borchmann P, , et al.. Radiotherapy (RT) to bulky (B) and extralymphatic (E) disease in combination with 6xR-CHOP-14 or R-CHOP-21 in young good-prognosis DLBCL patients: results of the 2x2 randomized Unfolder trial of the DSHNHL/GLA. JCO 2018; 36(15 suppl): 7574. doi: https://doi.org/10.1200/JCO.2018.36.15_suppl.7574 CrossrefGoogle Scholar

  • 44. Pfreundschuh M, , Christofyllakis K, , Altmann B, , Ziepert M, , Haenel M, , Viardot A, , et al.. Radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly DLBCL patients: results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL>60 study of the DSHNHL. JCO 2017; 35(15_suppl): 7506. doi: https://doi.org/10.1200/JCO.2017.35.15_suppl.7506 CrossrefGoogle Scholar

  • 45. Freeman CL, , Savage KJ, , Villa DR, , Scott DW, , Srour L, , Gerrie AS, , et al.. Long-Term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP. Blood 2021; 137: 929–38. doi: https://doi.org/10.1182/blood.2020005846 http://www.ncbi.nlm.nih.gov/pubmed/32871586 Crossref Medline ISIGoogle Scholar

  • 46. Dabaja BS, , Phan J, , Mawlawi O, , Medeiros LJ, , Etzel C, , Liang F-W, , et al.. Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphoma. Leuk Lymphoma 2013; 54: 2631–8. doi: https://doi.org/10.3109/10428194.2013.784967 http://www.ncbi.nlm.nih.gov/pubmed/23488661 Crossref Medline ISIGoogle Scholar

  • 47. Dupuis J, , Itti E, , Rahmouni A, , Hemery F, , Gisselbrecht C, , Lin C, , et al.. Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International workshop criteria. Ann Oncol 2009; 20: 503–7. doi: https://doi.org/10.1093/annonc/mdn671 http://www.ncbi.nlm.nih.gov/pubmed/19074215 Crossref Medline ISIGoogle Scholar

  • 48. Tokola S, , Kuitunen H, , Turpeenniemi-Hujanen T, , Kuittinen O. Significance of bulky mass and residual tumor-Treated with or without consolidative radiotherapy-To the risk of relapse in DLBCL patients. Cancer Med 2020; 9: 1966–77. doi: https://doi.org/10.1002/cam4.2798 http://www.ncbi.nlm.nih.gov/pubmed/31967739 Crossref Medline ISIGoogle Scholar

  • 49. Bobillo S, , Joffe E, , Lavery JA, , Sermer D, , Ghione P, , Noy A, , et al.. Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era. Blood 2021; 137: 39–48. doi: https://doi.org/10.1182/blood.2020005112 http://www.ncbi.nlm.nih.gov/pubmed/32730585 Crossref Medline ISIGoogle Scholar

  • 50. Giulino-Roth L. How I treat primary mediastinal B-cell lymphoma. Blood 2018; 132: 782–90. doi: https://doi.org/10.1182/blood-2018-04-791566 http://www.ncbi.nlm.nih.gov/pubmed/29976557 Crossref MedlineGoogle Scholar

  • 51. Dunleavy K, , Pittaluga S, , Maeda LS, , Advani R, , Chen CC, , Hessler J, , et al.. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 2013; 368: 1408–16. doi: https://doi.org/10.1056/NEJMoa1214561 http://www.ncbi.nlm.nih.gov/pubmed/23574119 Crossref Medline ISIGoogle Scholar

  • 52. Pinnix CC, , Dabaja B, , Ahmed MA, , Chuang HH, , Costelloe C, , Wogan CF, , et al.. Single-Institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys 2015; 92: 113–21. doi: https://doi.org/10.1016/j.ijrobp.2015.02.006 http://www.ncbi.nlm.nih.gov/pubmed/25863759 Crossref Medline ISIGoogle Scholar

  • 53. Shah NN, , Szabo A, , Huntington SF, , Epperla N, , Reddy N, , Ganguly S, , et al.. R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis. Br J Haematol 2018; 180: 534–44. doi: https://doi.org/10.1111/bjh.15051 http://www.ncbi.nlm.nih.gov/pubmed/29265182 Crossref Medline ISIGoogle Scholar

  • 54. Hayden AR, , Tonseth P, , Lee DG, , Villa D, , Gerrie AS, , Scott DW, , et al.. Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET-adapted approach. Blood 2020; 136: 2803–11. doi: https://doi.org/10.1182/blood.2019004296 http://www.ncbi.nlm.nih.gov/pubmed/32603413 Crossref Medline ISIGoogle Scholar

  • 55. Giulino-Roth L, , O'Donohue T, , Chen Z, , Bartlett NL, , LaCasce A, , Martin-Doyle W, , et al.. Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R. Br J Haematol 2017; 179: 739–47. doi: https://doi.org/10.1111/bjh.14951 http://www.ncbi.nlm.nih.gov/pubmed/29082519 Crossref Medline ISIGoogle Scholar

  • 56. Ceriani L, , Martelli M, , Gospodarowicz MK, , Ricardi U, , Ferreri AJM, , Chiappella A, , et al.. Positron emission tomography/computed tomography assessment after immunochemotherapy and irradiation using the Lugano classification criteria in the IELSG-26 study of primary mediastinal B-cell lymphoma. Int J Radiat Oncol Biol Phys 2017; 97: 42–9. doi: https://doi.org/10.1016/j.ijrobp.2016.09.031 http://www.ncbi.nlm.nih.gov/pubmed/27839910 Crossref Medline ISIGoogle Scholar

  • 57. Melani C, , Advani R, , Roschewski M, , Walters KM, , Chen CC, , Baratto L, , et al.. End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making. Haematologica 2018; 103: 1337–44. doi: https://doi.org/10.3324/haematol.2018.192492 http://www.ncbi.nlm.nih.gov/pubmed/29748435 Crossref Medline ISIGoogle Scholar

  • 58. Sehn LH, , Salles G. Diffuse large B-cell lymphoma. N Engl J Med 2021; 384: 842–58. doi: https://doi.org/10.1056/NEJMra2027612 http://www.ncbi.nlm.nih.gov/pubmed/33657296 Crossref MedlineGoogle Scholar

  • 59. Chiappella A, , Martelli M, , Angelucci E, , Brusamolino E, , Evangelista A, , Carella AM, , et al.. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. Lancet Oncol 2017; 18: 1076–88. doi: https://doi.org/10.1016/S1470-2045(17)30444-8 http://www.ncbi.nlm.nih.gov/pubmed/28668386 Crossref Medline ISIGoogle Scholar

  • 60. Younes A, , Sehn LH, , Johnson P, , Zinzani PL, , Hong X, , Zhu J, , et al.. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in Non-Germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol 2019; 37: 1285–95. doi: https://doi.org/10.1200/JCO.18.02403 http://www.ncbi.nlm.nih.gov/pubmed/30901302 Crossref Medline ISIGoogle Scholar

  • 61. Burggraaff CN, , de Jong A, , Hoekstra OS, , Hoetjes NJ, , Nievelstein RAJ, , Jansma EP, , et al.. Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 2019; 46: 65–79. doi: https://doi.org/10.1007/s00259-018-4103-3 http://www.ncbi.nlm.nih.gov/pubmed/30141066 Crossref Medline ISIGoogle Scholar

  • 62. Eertink JJ, , Burggraaff CN, , Heymans MW, , Dührsen U, , Hüttmann A, , Schmitz C, , et al.. Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients. Blood Adv 2021; 5: 2375–84. doi: https://doi.org/10.1182/bloodadvances.2021004467 http://www.ncbi.nlm.nih.gov/pubmed/33944897 Crossref Medline ISIGoogle Scholar

  • 63. Casasnovas R-O, , Ysebaert L, , Thieblemont C, , Bachy E, , Feugier P, , Delmer A, , et al.. FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study. Blood 2017; 130: 1315–26. doi: https://doi.org/10.1182/blood-2017-02-766691 http://www.ncbi.nlm.nih.gov/pubmed/28701367 Crossref Medline ISIGoogle Scholar

  • 64. Dührsen U, , Müller S, , Hertenstein B, , Thomssen H, , Kotzerke J, , Mesters R, , et al.. Positron emission Tomography-Guided therapy of aggressive non-Hodgkin lymphomas (petal): a multicenter, randomized phase III trial. J Clin Oncol 2018; 36: 2024–34. doi: https://doi.org/10.1200/JCO.2017.76.8093 http://www.ncbi.nlm.nih.gov/pubmed/29750632 Crossref Medline ISIGoogle Scholar

  • 65. Le Gouill S, , Ghesquières H, , Obéric L, , Morschhauser F, , Tilly H, , Ribrag V, , et al.. Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by lysA. Blood 2021; 137: 2307–20. doi: https://doi.org/10.1182/blood.2020008750 Crossref Medline ISIGoogle Scholar

  • 66. Hertzberg M, , Gandhi MK, , Trotman J, , Butcher B, , Taper J, , Johnston A, , et al.. Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14. Haematologica 2017; 102: 356–63. doi: https://doi.org/10.3324/haematol.2016.154039 http://www.ncbi.nlm.nih.gov/pubmed/28143954 Crossref Medline ISIGoogle Scholar

  • 67. Pardal E, , Coronado M, , Martín A, , Grande C, , Marín-Niebla A, , Panizo C, , et al.. Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial. Br J Haematol 2014; 167: 327–36. doi: https://doi.org/10.1111/bjh.13036 http://www.ncbi.nlm.nih.gov/pubmed/25066542 Crossref Medline ISIGoogle Scholar

  • 68. Kasamon YL, , Wahl RL, , Ziessman HA, , Blackford AL, , Goodman SN, , Fidyk CA, , et al.. Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning. Biol Blood Marrow Transplant 2009; 15: 242–8. doi: https://doi.org/10.1016/j.bbmt.2008.11.026 http://www.ncbi.nlm.nih.gov/pubmed/19167684 Crossref Medline ISIGoogle Scholar

  • 69. Stewart DA, , Kloiber R, , Owen C, , Bahlis NJ, , Duggan P, , Mansoor A, , et al.. Results of a prospective phase II trial evaluating interim positron emission tomography-guided high dose therapy for poor prognosis diffuse large B-cell lymphoma. Leuk Lymphoma 2014; 55: 2064–70. doi: https://doi.org/10.3109/10428194.2013.862242 http://www.ncbi.nlm.nih.gov/pubmed/24188476 Crossref Medline ISIGoogle Scholar

  • 70. Sehn LH, , Hardy ELG, , Gill KK, , Al-Tourah AJ, , Shustik J, , Macpherson NA, , et al.. Phase 2 trial of interim PET Scan-Tailored therapy in patients with advanced stage diffuse large B-cell lymphoma (DLBCL) in British Columbia (bc. Blood 2014; 124: 392. doi: https://doi.org/10.1182/blood.V124.21.392.392 CrossrefGoogle Scholar

  • 71. Held G, , Murawski N, , Ziepert M, , Fleckenstein J, , Pöschel V, , Zwick C, , et al.. Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. J Clin Oncol 2014; 32: 1112–8. doi: https://doi.org/10.1200/JCO.2013.51.4505 http://www.ncbi.nlm.nih.gov/pubmed/24493716 Crossref Medline ISIGoogle Scholar

  • 72. Kostakoglu L, , Goldsmith SJ, , Leonard JP, , Christos P, , Furman RR, , Atasever T, , et al.. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer 2006; 107: 2678–87. doi: https://doi.org/10.1002/cncr.22276 http://www.ncbi.nlm.nih.gov/pubmed/17063502 Crossref Medline ISIGoogle Scholar

  • 73. Dabaja BS, , Hess K, , Shihadeh F, , Podoloff DA, , Medeiros LJ, , Mawlawi O, , et al.. Positron emission tomography/computed tomography findings during therapy predict outcome in patients with diffuse large B-cell lymphoma treated with chemotherapy alone but not in those who receive consolidation radiation. Int J Radiat Oncol Biol Phys 2014; 89: 384–91. doi: https://doi.org/10.1016/j.ijrobp.2014.02.015 http://www.ncbi.nlm.nih.gov/pubmed/24721592 Crossref Medline ISIGoogle Scholar

  • 74. Phan J, , Mazloom A, , Medeiros LJ, , Zreik TG, , Wogan C, , Shihadeh F, , et al.. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol 2010; 28: 4170–6. doi: https://doi.org/10.1200/JCO.2009.27.3441 http://www.ncbi.nlm.nih.gov/pubmed/20713859 Crossref MedlineGoogle Scholar

  • 75. Marcheselli L, , Marcheselli R, , Bari A, , Liardo EV, , Morabito F, , Baldini L, , et al.. Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2011; 52: 1867–72. doi: https://doi.org/10.3109/10428194.2011.585526 http://www.ncbi.nlm.nih.gov/pubmed/21663499 Crossref Medline ISIGoogle Scholar

  • 76. Dorth JA, , Prosnitz LR, , Broadwater G, , Diehl LF, , Beaven AW, , Coleman RE, , et al.. Impact of consolidation radiation therapy in stage III-IV diffuse large B-cell lymphoma with negative post-chemotherapy radiologic imaging. Int J Radiat Oncol Biol Phys 2012; 84: 762–7. doi: https://doi.org/10.1016/j.ijrobp.2011.12.067 http://www.ncbi.nlm.nih.gov/pubmed/22420972 Crossref Medline ISIGoogle Scholar

  • 77. Shi Z, , Das S, , Okwan-Duodu D, , Esiashvili N, , Flowers C, , Chen Z, , et al.. Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy. Int J Radiat Oncol Biol Phys 2013; 86: 569–77. doi: https://doi.org/10.1016/j.ijrobp.2013.02.007 http://www.ncbi.nlm.nih.gov/pubmed/23540349 Crossref Medline ISIGoogle Scholar

  • 78. Shi Z, , Esiashvili N, , Flowers C, , Das S, , Khan MK. Renewed interest in the role of consolidative radiotherapy in advanced stage diffuse large B-cell lymphoma. Leuk Lymphoma 2013; 54: 2122–30. doi: https://doi.org/10.3109/10428194.2013.779687 http://www.ncbi.nlm.nih.gov/pubmed/23445367 Crossref Medline ISIGoogle Scholar

  • 79. Kwon J, , Kim IH, , Kim BH, , Kim TM, , Heo DS. Additional survival benefit of involved-lesion radiation therapy after R-CHOP chemotherapy in limited stage diffuse large B-cell lymphoma. Int J Radiat Oncol Biol Phys 2015; 92: 91–8. doi: https://doi.org/10.1016/j.ijrobp.2014.12.042 http://www.ncbi.nlm.nih.gov/pubmed/25721091 Crossref Medline ISIGoogle Scholar

  • 80. Vargo JA, , Gill BS, , Balasubramani GK, , Beriwal S. Treatment selection and survival outcomes in early-stage diffuse large B-cell lymphoma: do we still need consolidative radiotherapy? J Clin Oncol 2015; 33: 3710–7. doi: https://doi.org/10.1200/JCO.2015.61.7654 http://www.ncbi.nlm.nih.gov/pubmed/26261253 Crossref Medline ISIGoogle Scholar

  • 81. Odejide OO, , Cronin AM, , Davidoff AJ, , LaCasce AS, , Abel GA. Limited stage diffuse large B-cell lymphoma: comparative effectiveness of treatment strategies in a large cohort of elderly patients. Leuk Lymphoma 2015; 56: 716–24. doi: https://doi.org/10.3109/10428194.2014.930853 http://www.ncbi.nlm.nih.gov/pubmed/24913508 Crossref Medline ISIGoogle Scholar

  • 82. Wirth A, , Mikhaeel NG. Pet response-guided radiotherapy for advanced DLBCL? Blood 2021; 137: 866–7. doi: https://doi.org/10.1182/blood.2020008740 http://www.ncbi.nlm.nih.gov/pubmed/33599757 Crossref Medline ISIGoogle Scholar

  • 83. Balzarotti M, , Ricardi U, , Spina M, , Monagheddu C, , Tucci A, , Cavallo F, , et al.. PET-DRIVEN radiotherapy in patients with low risk diffuse large B-cell lymphoma (DLBCL): the DLCL10 multicenter phase 2 trial by FONDAZIONE ITALIANA LINFOMI (FIL. Hematological Oncology 2019; 37(S2): 253–4. doi: https://doi.org/10.1002/hon.62_2630 Crossref MedlineGoogle Scholar

  • 84. Pfreundschuh M, , Ziepert M, , Reiser M, , Poeschel V, , Wilhelm S, , Gaska T, , e al, , et al.. The role of radiotherapy to bulky disease in the rituximab era: results from two prospective trials of the German high-grade non-Hodgkin- lymphoma study group (DSHNHL) for elderly patients with DLBCL. Blood 2008; 112: 584. doi: https://doi.org/10.1182/blood.V112.11.584.584 CrossrefGoogle Scholar

  • 85. Spaepen K, , Stroobants S, , Dupont P, , Vandenberghe P, , Thomas J, , de Groot T, , et al.. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 2002; 13: 1356–63. doi: https://doi.org/10.1093/annonc/mdf256 http://www.ncbi.nlm.nih.gov/pubmed/12196360 Crossref Medline ISIGoogle Scholar

  • 86. Dührsen U, , Müller S, , Hertenstein B, , Thomssen H, , Kotzerke J, , Mesters R, , et al.. Positron emission Tomography-Guided therapy of aggressive non-Hodgkin lymphomas (petal): a multicenter, randomized phase III trial. J Clin Oncol 2018; 36: 2024–34. doi: https://doi.org/10.1200/JCO.2017.76.8093 http://www.ncbi.nlm.nih.gov/pubmed/29750632 Crossref Medline ISIGoogle Scholar

  • 87. Mamot C, , Klingbiel D, , Hitz F, , Renner C, , Pabst T, , Driessen C, , et al.. Final results of a prospective evaluation of the predictive value of interim positron emission tomography in patients with diffuse large B-cell lymphoma treated with R-CHOP-14 (SAKK 38/07. J Clin Oncol 2015; 33: 2523–9. doi: https://doi.org/10.1200/JCO.2014.58.9846 http://www.ncbi.nlm.nih.gov/pubmed/26150440 Crossref Medline ISIGoogle Scholar

  • 88. Jegadeesh N, , Rajpara R, , Esiashvili N, , Shi Z, , Liu Y, , Okwan-Duodu D, , et al.. Predictors of local recurrence after rituximab-based chemotherapy alone in stage III and IV diffuse large B-cell lymphoma: guiding decisions for consolidative radiation. Int J Radiat Oncol Biol Phys 2015; 92: 107–12. doi: https://doi.org/10.1016/j.ijrobp.2015.01.025 http://www.ncbi.nlm.nih.gov/pubmed/25863758 Crossref Medline ISIGoogle Scholar

  • 89. Ng AK, , Dabaja BS, , Hoppe RT, , Illidge T, , Yahalom J. Re-Examining the role of radiation therapy for diffuse large B-cell lymphoma in the modern era. J Clin Oncol 2016; 34: 1443–7. doi: https://doi.org/10.1200/JCO.2015.64.9418 http://www.ncbi.nlm.nih.gov/pubmed/26903576 Crossref Medline ISIGoogle Scholar

  • 90. Wirth A. The rationale and role of radiation therapy in the treatment of patients with diffuse large B-cell lymphoma in the rituximab era. Leuk Lymphoma 2007; 48: 2121–36. doi: https://doi.org/10.1080/10428190701636468 http://www.ncbi.nlm.nih.gov/pubmed/17990176 Crossref Medline ISIGoogle Scholar

  • 91. Moser EC, , Kluin-Nelemans HC, , Carde P, , Meerwaldt JH, , Tirelli U, , Aleman BMP, , et al.. Impact of involved field radiotherapy in partial response after doxorubicin-based chemotherapy for advanced aggressive non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 2006; 66: 1168–77. doi: https://doi.org/10.1016/j.ijrobp.2006.05.006 http://www.ncbi.nlm.nih.gov/pubmed/16887289 Crossref Medline ISIGoogle Scholar

Newly Published, ePub Ahead of Issue

© 2021 The Authors. Published by the British Institute of Radiology


History

  • RevisedJuly 27,2021
  • ReceivedMay 10,2021
  • AcceptedAugust 19,2021
  • Published onlineSeptember 14,2021

Metrics